Viasys acquires Navion catheter guidance system:
This article was originally published in Clinica
Conshohocken, Pennsylvania-based Viasys Healthcare's MedSystems business has acquired the assets of Navion Biomedical, a Stoughton, Massachusetts-based firm that makes the Navigator Bionavigation system for the placement of catheters. The system consists of a disposable stylet or guidewire and a hand-held, battery-operated locating instrument. The instrument uses low-level, high-frequency magnetic fields to communicate with the catheter or guidewire, enabling them to be placed accurately at the patient's bedside. Without such a system, positioning of peripherally inserted central catheters and central venous catheters must be verified by X-ray, and can involve costly and time-consuming repositioning and confirmatory X-rays.
You may also be interested in...
Officials from the US Food and Drug Administration cited their reasons for refusing to review new applications for companies with unresolved data integrity failures.
However, Vaccinex sees possible efficacy for SEMA4D inhibition in later-stage Huntington’s as well as Alzheimer’s disease. Pepinemab is also being studied with Keytruda in head-and-neck cancer.
In last year’s acquisition, Bristol Myers Squibb agreed to pay Celgene investors another $9 per share based on three approvals, including idecabtagene vicleucel (bb2121) by 30 March 2021.